CamDiab Archives - Medical Design Sourcing

Ypsomed: closed-loop insulin dosing improves health of pregnant women with type 1 diabetes

A study showed that the mylife Loop system improves the health of pregnant women with type 1 diabetes. [image courtesy of Ypsomed]Ypsomed today announced clinical study data demonstrating the benefits of its hybrid closed-loop insulin delivery system for pregnant women.

Pregnant women with type 1 diabetes and their babies benefitted from the automated insulin delivery system based on the CamDiab CamAPS FX algorithm. The New England Journal of Medicine published these outcomes from Ypsomed’s AiDAPT clinical study.

Ypsomed says the CamAPS FX is the only automated insulin delivery (AID) algorithm approved for pregnant women with type 1 diabetes. The mylife Loop system combines that algorithm with the Ypsomed YpsoPump and the Abbott FreeStyle Libre 3 or Dexcom G6 CGM.

Together, they form an intelligent and automated insulin delivery (AID) system for people with type 1 diabetes. Users can better control glucose levels and alleviate the burden of daily diab…

Abbott FreeStyle Libre 3 authorized for automated insulin delivery in UK

[Image from Ypsomed]Abbott (NYSE:ABT) announced that its FreeStyle Libre 3 continuous glucose monitor (CGM) received UK authorization for use in automated insulin delivery.

Authorization enables FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump and CamDiab’s CamAPS FX mobile app. The company called this a “major step forward” for type 1 diabetes management in the United Kingdom.

At the end of last year, the company received authorization to integrate FreeStyle Libre 3 with the mylife Loop from Ypsomed and CamDiab. That collaboration began in Germany. Abbott said at the time that it planned launches in the UK, Switzerland and the Netherlands in the first half of this year.

Combined, the technologies form an intelligent process to deliver insulin in the form of an artificial pancreas. The closed-loop system utilizes real-time glucose data to create an automated insulin delivery (AID) system. It remov…

The 10 biggest diabetes tech stories from 2022

Some of the biggest diabetes technology developments in 2022. These include the Dexcom G7 (top left), Insulet Omnipod 5 (bottom left), Senseonics Eversense E3 (top right) and Abbott FreeStyle Libre 3 (bottom right. 2022 represented a landmark year for next-generation diabetes technologies. Here are the biggest stories from the past year.

Some companies picked up major regulatory nods. Others experienced major regulatory setbacks.

Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from, but here are 10 big ones that stood out:

Dexcom G7 receives FDA clearance

The long-awaited regulatory nod for Dexcom’s next-generation continuous glucose monitor (CGM) finally came in December.

Some suggested that San Diego-based Dexcom may pick up clearance as soon as summer 2022. However, a software change recommended by the FDA, plus COVID-19-related backlog, delayed proceedings.

Dexcom COO Ja…

Abbott FreeStyle Libre 3 links with automated insulin delivery system for use in Europe

The sensor for the next-generation FreeStyle Libre 3 CGM is the same size as two U.S. pennies stacked together. [Image courtesy of Abbott]Abbott (NYSE:ABT) today announced compatibility between its FreeStyle Libre 3 sensor and the mylife Loop from Ypsomed and CamDiab.

Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data.

The companies launched their automated insulin delivery (AID) system in Germany. They intend to offer it in additional European countries in 2023.

“Our FreeStyle Libre portfolio is already helping to improve the lives of 4.5 million people around the world who are living with diabetes,” said Jared Watkin, SVP of Abbott’s diabetes care business. “We’re partnering with diabetes and digital health technology leaders like Ypsomed and CamDiab to deliver new innovative solutions that make diabetes care as easy as possible, so people can spend less time worr…

Ypsomed, CamDiab launch first automated insulin dosing system with Abbott FreeStyle Libre 3

[Image from Ypsomed]Ypsomed announced that its mylife Loop now has authorization to work with the Abbott FreeStyle Libre 3 sensor in Germany.

The Ypsomed mylife YpsoPump combines with the CamDiab mylife CamAPS FX algorithm and FreeStyle Libre 3. Together, they form an intelligent and automated insulin delivery (AID) system for people with type 1 diabetes. Users can better control glucose levels and alleviate the burden of daily diabetes management.

Get the full story at our sister site, Drug Delivery Business News.

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.

From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.

Here are five of the biggest stories to come out of ATTD 2022:

Dexcom’s G7 is accurate in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

Get the full story at our sister site, Drug Delivery Business News.

Abbott, Camdiab, Ypsomed forge partnership for automated insulin delivery

[Image from Abbott, CamDiab and Ypsomed]Abbott (NYSE:ABT) announced today that it partnered with CamDiab and Ypsomed (SWX:YPSN) to produce an integrated automated insulin delivery (AID) system.

The partnership, which the companies announced at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, Spain, seeks to develop and commercialize the integrated AID system with an initial focus centered around European countries.

According to a news release, the partnership aims to design the integrated AID system to connect Abbott’s FreeStyle Libre 3 sensor — touted as the world’s smallest and most accurate continuous glucose monitoring sensor (CGM) with readings every minute — to CamDiab’s CamAPS FX mobile app, which connects with Ypsomed’s mylife YpsoPump.

Get the full story at our sister site, Drug Delivery Business News.

Ypsomed partners with CamDiab on smartphone-based automated insulin delivery

[Image from Ypsomed]Ypsomed (SWX:YPSN) announced today that it partnered with CamDiab to collaborate on managing automated insulin delivery with a mobile app.

The partnership aims to launch CamDiab’s CamAPS FX app for managing glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach, for automated insulin delivery (AID) with Ypsomed’s MyLife YpsoPump system during the first half of 2022.

Get the full story at our sister site, Drug Delivery Business News.